每经头条（nbdtoutiao）——伤亡180万人！俄乌冲突四周年，陷入谈判死局、战场僵局、经济困局！谁 为战争买单 （记者 曾健辉） 每经AI快讯，赛诺医疗2月25日晚间发布公告称，2026年2月24日，公司召开第三届董事会第十二次会 议，审议通过《赛诺医疗科学技术股份有限公司关于以集中竞价交易方式回购股份方案的议案》，并将 该议案提交公司股东会审议。回购的股份拟用于员工持股计划或股权激励。本次回购的资金总额不低于 人民币1500万元（含）且不超过人民币3000万元（含），其中银行回购专项贷款金额不超过2700万元 （含）.本次回购股份的价格不超过人民币35.1元/股（含），该价格不高于公司董事会通过回购决议前 30个交易日公司股票交易均价的150%。回购期限自公司股东会审议通过回购股份方案之日起12个月 内.。 ...

每经AI快讯，联影医疗2月25日晚间发布2025年度业绩快报，营业收入约138.21亿元，同比增加 34.18%；归属于上市公司股东的净利润约18.88亿元，同比增加49.6%；基本每股收益2.29元，同比增加 48.7%。 每经头条（nbdtoutiao）——伤亡180万人！俄乌冲突四周年，陷入谈判死局、战场僵局、经济困局！谁 为战争买单 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...

Core Viewpoint - Sino Medical announced a total operating revenue of 525.41 million yuan for the fiscal year 2025, representing a year-on-year growth of 14.53% [1] - The net profit attributable to the parent company reached 47.29 million yuan, showing a significant year-on-year increase of 3,057.05% [1] - The non-recurring net profit was reported at 33.96 million yuan, reflecting a year-on-year growth of 293.82% [1] Financial Performance - The substantial increase in net profit is attributed to continuous revenue growth, a decrease in costs, and a reduction in certain expenses, along with a low base from the previous year [1] - As of the end of the reporting period, total assets amounted to 1.35 billion yuan, which is a 3.78% increase compared to the end of the previous year [1] - The equity attributable to the parent company was 927.64 million yuan, marking a growth of 7.01% [1] Data Notes - The figures provided are preliminary estimates and may differ from the final annual report [1]

Core Viewpoint - 康众医疗 reported a total operating revenue of 321 million yuan for the year 2025, representing a year-on-year growth of 7.52%, driven by the steady advancement of new product applications, market promotion, and enhanced product competitiveness [1] Financial Performance - The company recorded an operating profit of -10.76 million yuan, a decrease of 28.33 million yuan compared to the same period last year [2] - The total profit amounted to -10.98 million yuan, down by 28.67 million yuan year-on-year [2] - The net profit attributable to the parent company was -7.10 million yuan, a decline of 24.75 million yuan compared to the previous year [2] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -15.63 million yuan, a decrease of 21.58 million yuan year-on-year [2] - Basic earnings per share were -0.08 yuan, down by 0.28 yuan from the same period last year [2] Asset and Equity Position - At the end of the reporting period, the company's total assets were 982.51 million yuan, an increase of 1.61% year-on-year [3] - The equity attributable to the parent company was 849.90 million yuan, a decrease of 1.47% compared to the previous year [3] - The net asset value per share attributable to the parent company was 9.73 yuan, down by 1.47% year-on-year [3]

Core Viewpoint - Jiangsu Kangzhong announced a total operating revenue of 320.53 million yuan for 2025, representing a year-on-year increase of 7.52%, primarily due to the promotion of new product conversion and market expansion [1] Financial Performance - Operating profit was -10.76 million yuan, total profit was -10.98 million yuan, and net profit attributable to shareholders was -7.10 million yuan, all significantly decreased compared to the same period last year [1] - The basic earnings per share were -0.08 yuan, a decrease of 0.28 yuan year-on-year [1] Asset and Equity Position - Total assets at the end of the reporting period were 982.51 million yuan, an increase of 1.61% year-on-year [1] - Equity attributable to shareholders was 849.90 million yuan, a decrease of 1.47% year-on-year [1]

Core Viewpoint - The company has terminated its equity acquisition without any payment or breach of contract, and this decision has not adversely affected its financial status or normal operations [1] Group 1: Company Actions - The company will continue to strictly adhere to regulatory requirements and make prudent external investment decisions [1] - The company aims to enhance the transparency of its information disclosure [1] - The company is committed to deepening its focus on the medical device sector to solidify its intrinsic value through stable operational performance [1] Group 2: Investor Relations - The company emphasizes the importance of strengthening communication with investors [1] - The company is dedicated to safeguarding the legitimate rights and interests of all shareholders [1]

格隆汇2月25日丨联影医疗(688271.SH)公布2025年度业绩快报，公司2025年度实现营业总收入138.21亿 元，同比增长34.18%；实现归属于母公司所有者的净利润18.88亿元，同比增长49.60%；实现归属于母 公司所有者的扣除非经常性损益的净利润17.88亿元，同比增长77.01%。 报告期内，公司围绕长期竞争力建设，系统推进创新产品导入、全球市场布局深化、供应链体系优化及 核心技术能力积累。中国市场在大规模医疗设备更新政策于2025年进入常态化、专业化实施阶段的背景 下，高端医学影像、放疗及基层诊疗能力建设相关设备需求持续释放，行业整体规模较上年同期明显回 升。公司在国内市场占有率持续提升并保持行业领先地位，中国市场收入规模实现显著增长，经营质量 与盈利能力同步增强。 ...

Group 1 - The core point of the article is that 乐心医疗 (Lixun Medical) has reported its total number of shareholders as of February 13, 2026, which stands at 23,363 [1]

联影医疗公告称，2025年度实现营业总收入138.21亿元，同比增长34.18%；归属于母公司所有者的净利 润18.88亿元，同比增长49.60%；扣除非经常性损益的净利润17.88亿元，同比增长77.01%。2025年末， 公司总资产328.00亿元，同比增长17%；归属于母公司的所有者权益215.90亿元，同比增长8.48%。业绩 增长得益于创新产品导入、全球市场布局深化等，未来整体经营规模与运营质效有望进一步提升。数据 为初步核算，未经审计。 ...

联影医疗(688271.SH)公告称，联影医疗发布2025年度业绩快报，营业总收入达到138.2亿元，同比增长 34.18%。归属于母公司所有者的净利润为18.88亿元，同比增长49.60%。主要因素包括创新产品推出、 高端市场认可提升、海外业务增长等。本公告数据为初步核算，具体以年度报告为准。 ...